The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | Data from the Phase 3 CASSIOPEIA trial: D-VTd vs. VTd
Philippe Moreau, University Hospital, Nantes, France, presents the results of part 1 of the CASSIOPEIA trial (NCT02541383). This trial investigated bortezomib, thalidomide, dexamethasone (VTD) followed by stem cell transplantation, followed by two cycles of consolidation therapy with VTD with or without daratumumab in newly diagnosed multiple myeloma. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
